Skip to main content

REVIEW article

Front. Cardiovasc. Med.
Sec. Cardio-Oncology
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1408983

Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma

Provisionally accepted
Jun Du Jun Du 1Zeyu Chen Zeyu Chen 2Xiao-Ran Gu Xiao-Ran Gu 2Ting Wang Ting Wang 1Zou-fang Huang Zou-fang Huang 3*
  • 1 Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  • 2 Department of Basic Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
  • 3 Ganzhou Key Laboratory of Hematology, Department of Hematology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province, China

The final, formatted version of the article will be published soon.

    Adverse events of atrial fibrillation (AF) have been commonly reported in lymphoma patients in treating Bruton's tyrosine kinase inhibitors (BTKi). The incidence rate of AF can vary depending on the specific types of BTKi and the patient population.Totally 42 published studies have revealed that the overall incidence rate of AF is 5% (95% CI 4%-7%). By performing a subtype single-rate analysis, the secondgeneration BTKi shows a lower AF incidence rate and lower cardiovascular toxicity.In the subtype single-rate analysis, we conclude the different AF incidence rates of Ibrutinib (10%, 95% CI 7%-13%), Acalabrutinib (4%, 95% CI 1%-6%), Orelabrutinib (0%, 95% CI 0%-1%), and Zanubrutinib (0%, 95% CI 0%-1%). The comprehensive analysis of AF inspires us to better predict and manage AF and other cardiovascular events in treating lymphoma. Meticulous evaluation, collaboration between cardiologists and hematologists, and discovery of new biomarkers are essential for its management.

    Keywords: Atrial Fibrillation, Bruton tyrosine kinase inhibitors, cardiovascular toxicity, Lymphoma, Ibrutinib

    Received: 29 Mar 2024; Accepted: 12 Jul 2024.

    Copyright: © 2024 Du, Chen, Gu, Wang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zou-fang Huang, Ganzhou Key Laboratory of Hematology, Department of Hematology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.